Stocktoria
Aligos Therapeutics, Inc. ALGS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16
Aligos Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 |
| R&D expense | $69.5M | $70.3M | $73.0M | $85.1M | $104.2M |
| Operating income | -$88.0M | -$89.2M | -$88.1M | -$97.6M | -$128.3M |
| Income tax | $314,000 | $331,000 | $795,000 | $106,000 | $143,000 |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M | -$128.3M |
| EPS (diluted) | $-2.45 | $-20.94 | $-34.20 | $-2.25 | — |
| Operating cash flow | -$82.5M | -$80.7M | -$79.0M | -$79.4M | -$115.7M |
| Free cash flow | — | -$80.9M | -$79.0M | -$80.3M | -$116.6M |
| Cash & equivalents | $18.3M | $37.0M | $135.7M | $81.3M | $186.8M |
| Total assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M |
| Total liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M |
| Shareholders' equity | $53.5M | -$29.0M | $92.1M | $103.9M | $184.7M |
Source: SEC EDGAR filings · CIK 0001799448 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.